Indeed, to limit the pathological pathway activation in several cancers, some VEGF and VEGF receptor (VEGFR) inhibitors have been developed, including sorafenib, sunitinib, vandetanib, lenvatinib, axitinib, bevacizumab, ramucirumab, cabozantinib, and pazopanib [13]. This evidence concerns the gene VEGFA and cancer.